ADXN — +73% premarket as spin-out closes $105M Series B

Addex Therapeutics surged about 73% in premarket trading after its spin-out Neurosterix closed a $105 million Series B financing on November 11, valuing Addex's 8.5% stake at $18.6 million. Addex did not participate in the round. The financing backs Neurosterix's schizophrenia program, which recently completed Phase 1 studies of NTX-253.